.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,399,450

« Back to Dashboard

Details for Patent: 8,399,450

Title:Compounds and compositions as protein kinase inhibitors
Abstract: The invention provides novel pyrimidine and pyridine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine and pyridine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, focal adhesion kinase (FAK), zeta-chain-associated protein kinase 70 (ZAP-70), insulin-like growth factor (IGF-1R), or a combination thereof.
Inventor(s): Michellys; Pierre-Yves (San Marcos, CA), Pei; Wei (San Diego, CA), Marsilje; Thomas H. (San Diego, CA), Lu; Wenshuo (San Diego, CA), Chen; Bei (San Diego, CA), Uno; Tetsuo (San Diego, CA), Jin; Yunho (San Diego, CA), Jiang; Tao (San Diego, CA)
Assignee: IRM LLC (Hamilton, BM)
Filing Date:Jun 29, 2011
Application Number:13/172,357
Claims:1. A compound having Formula (1): ##STR00363## or pharmaceutically acceptable salts thereof; wherein W is ##STR00364## A.sup.1 and A.sup.4 are independently C; each A.sup.2 and A.sup.3 is C; B and C are independently an optionally substituted 5-7 membered carbocyclic ring, aryl, heteroaryl or heterocyclic ring containing N, O or S; Z.sup.1, Z.sup.2 and Z.sup.3 are independently NR.sup.11, C.dbd.O, CR--OR, (CR.sub.2).sub.1-2 or .dbd.C--R.sup.12; R.sup.1 is halo or C.sub.1-6 alkyl; R.sup.2 is H; R.sup.3 is SO.sub.2R.sup.12 or cyano; R.sup.4, R.sup.7 and R.sup.10 are independently H; R, R.sup.5 and R.sup.5' are independently H or C.sub.1-6 alkyl; R.sup.6 is --OR.sup.12; one of R.sup.8 and R.sup.9 is (CR.sub.2).sub.qY and the other is C.sub.1-6 alkyl; R.sup.11 is H, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, (CR.sub.2).sub.pCO.sub.1-2R, (CR.sub.2).sub.pOR, (CR.sub.2).sub.pR.sup.13, (CR.sub.2).sub.pNRR.sup.12, (CR.sub.2).sub.pCONRR.sup.12 or (CR.sub.2).sub.pSO.sub.1-2R.sup.12; R.sup.12 and R.sup.13 are independently an optionally substituted 3-7 membered saturated or partially unsaturated carbocyclic ring, or a 5-7 membered heterocyclic ring comprising N, O and/or S; aryl or heteroaryl; or R.sup.12 is H or C.sub.1-6 alkyl; Y is an optionally substituted 3-12 membered carbocyclic ring, a 5-12 membered aryl, or a 5-12 membered heteroaryl comprising N, O and/or S and attached to A.sup.2 or A.sup.3 or both via a carbon atom of said heteroaryl n is 4; p is 0-4; and q is 0.

2. The compound of claim 1, wherein R.sup.12 is C.sub.1-6 alkyl, C.sub.3-7 cycloalkyl, C.sub.3-7 cycloalkenyl, pyrrolidinyl, piperazinyl, piperidinyl or morpholinyl.

3. The compound of claim 1, wherein R.sup.6 is --O(C.sub.1-6 alkyl).

4. The compound of claim 1, wherein R.sup.5 and R.sup.5' are H.

5. The compound of claim 1, wherein said compound is of Formula (2): ##STR00365## or pharmaceutically acceptable salts thereof; wherein R.sup.1 is halo or C.sub.1-6 alkyl; R.sup.2 is H; R.sup.6 is isopropoxy or methoxy; Y is an optionally substituted C.sub.3-7 cycloalkyl, C.sub.3-7 cycloalkenyl, or phenyl; or Y is pyridyl, pyrazolyl, isoxazolyl, imidazolyl, thiazolyl, or benzimidazolyl, each of which is attached to the phenyl ring via a carbon atom; and R.sup.3, R.sup.4, R.sup.8, R.sup.9 and n are as defined in claim 1.

6. The compound of claim 1, wherein said compound is of Formula (3A) or (3B): ##STR00366## wherein B and C together form ##STR00367## Z.sup.1, Z.sup.2 and Z.sup.3 together form ##STR00368## or tautomers thereof; R.sup.1 is halo or C.sub.1-6 alkyl; R.sup.2 is H; and R.sup.6 is isopropoxy or methoxy.

7. The compound of claim 6, wherein each R.sup.11 is (CR.sub.2).sub.pCO.sub.1-2R, (CR.sub.2).sub.pOR, (CR.sub.2).sub.pR.sup.13, (CR.sub.2).sub.pNRR.sup.12 or (CR.sub.2).sub.pCONRR.sup.12; R and R.sup.12 are independently H or C.sub.1-6 alkyl; and R.sup.13 is an optionally substituted piperidinyl, azetidiyl, tetrahydropyranyl, cyclohexyl, morpholinyl, pyrrolidinyl, heptamethyleneimine, octamethyleneimine, a bicyclic amine or diamine derivative, quinuclidin-3-yl, 8-methyl-8-aza-bicyclo[3.2.1]oct-6-yl], or 9-methyl-9-aza-bicyclo[4.2.1]nonan-7-yl.

8. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.

9. A combination comprising a compound of claim 1, or pharmaceutically acceptable salts thereof, and a chemotherapeutic agent.

10. The compound of claim 1, wherein said compound is selected from the group consisting of ##STR00369## ##STR00370## ##STR00371## ##STR00372## ##STR00373## ##STR00374## ##STR00375## ##STR00376## ##STR00377## or a pharmaceutically acceptable salt thereof.

11. The compound of claim 5, wherein said compound is selected from the group consisting of ##STR00378## ##STR00379## ##STR00380## ##STR00381## ##STR00382## ##STR00383## ##STR00384## ##STR00385## ##STR00386## ##STR00387## ##STR00388## ##STR00389## ##STR00390## ##STR00391## or a pharmaceutically acceptable salt thereof.

12. The compound of claim 1, wherein said compound is selected from the group consisting of ##STR00392## ##STR00393## ##STR00394## ##STR00395## ##STR00396## ##STR00397## ##STR00398## ##STR00399## ##STR00400## ##STR00401## ##STR00402## ##STR00403## ##STR00404## ##STR00405## ##STR00406## ##STR00407## ##STR00408## ##STR00409## ##STR00410## ##STR00411## ##STR00412## ##STR00413## or pharmaceutically acceptable salts thereof.

13. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 10 and a pharmaceutically acceptable carrier.

14. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 11 and a pharmaceutically acceptable carrier.

15. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 12 and a pharmaceutically acceptable carrier.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc